Today EBX announced positive results from its Phase 1b clinical trial evaluating EBX-102, the Company’s next-generation oral full-spectrum microbiome product, in patients with liver cirrhosis.

Today we announced that results from our IMPuLCE Phase 1b trial evaluating EBX-102, the Company’s next-generation full-spectrum microbiome product, in patients with liver cirrhosis will be shared as an oral presentation at the European Association for the Study of the Liver (EASL) Congress 2025, taking place in Amsterdam, the Netherlands from 7-10 May 2025.

Today we announced that data from its Phase 2a TrIuMPH trial of EBX-102-02 in 122 adults with IBS-C has been selected for a late-breaking oral presentation at Digestive Disease Week® (DDW) 2025, to be held 3–6 May in San Diego, USA.

EnteroBiotix will be attending BIO Europe, Stockholm on 4-6 November 2024.

EnteroBiotix will be attending BIO Future, New York on 28-30 October 2024.

EnteroBiotix will be attending Bio International Convention, 3-6 June 2024.